Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 30;14(9):4153-4158.
doi: 10.21037/tlcr-2025-639. Epub 2025 Sep 12.

Refining maintenance strategies for metastatic nonsquamous non-small cell lung cancer: insights from the KEYLYNK-006 study

Marcel Kemper  1   2 , Frank Griesinger  3 , Annalen Bleckmann  1   2
Affiliations
Editorial

Refining maintenance strategies for metastatic nonsquamous non-small cell lung cancer: insights from the KEYLYNK-006 study

Marcel Kemper et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi); immunotherapy; maintenance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-639/coif). M.K. received honoraria or travel grants not related to this manuscript from Pierre Fabre, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Janssen-Cilag, Novartis, Roche Pharma, and Takeda Pharma. F.G. received institutional grants not related to this manuscript from AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, Novartis, Roche, MSD, Pfizer, Takeda, Siemens, Amgen, GSK, Sanofi, Regeneron, Gilead, Janssen-Cilag and Daiichi-Sankyo; and received honoraria or travel grants not related to this manuscript from AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Novartis, Roche, MSD, Pfizer, Takeda, Siemens, Amgen, Tesaro/GSK, Sanofi, Daiichi-Sankyo, Beigene, Regereron, Gilead and IPSEN. A.B. received honoraria or travel grants not related to this manuscript from Bayer, BMS, Takeda, MSD, Boehringer, AstraZeneca, Sanofi, Pfizer, Lilly, Amgen, RG GmbH, Roche, Novartis, Janssen, and Daiichi. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Study design of the randomized phase 3 KEYLYNK-006 trial. Patients with stage IV nonsquamous NSCLC received induction therapy with pembrolizumab, pemetrexed, and platinum chemotherapy (n=1,003). Those with CR, PR, or SD (n=672) were randomized 1:1 to maintenance pembrolizumab plus olaparib (Arm A) or pemetrexed (Arm B) for up to 31 cycles. Dual primary endpoints were PFS and OS. ALK, anaplastic lymphoma kinase; AUC, area under curve; BICR, blinded independent central review; BID, bis in die; CR, complete response; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; IV, intravenous; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PO, per os; PR, partial response; Q3W, quaque 3 weeks; QoL, quality of life; RECIST, Response Evaluation Criteria in Solid Tumors; ROS1, c-ros oncogene 1; SD, stable disease.
See this image and copyright information in PMC

Comment on

References

    1. Gray JE, Schenker M, Şendur MAN, et al. The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol 2025;20:219-32. 10.1016/j.jtho.2024.10.026 - DOI - PubMed
    1. Shen J, Zhao W, Ju Z, et al. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 2019;79:311-9. 10.1158/0008-5472.CAN-18-1003 - DOI - PMC - PubMed
    1. Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep 2019;9:1853. 10.1038/s41598-019-38534-6 - DOI - PMC - PubMed
    1. Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res 2017;23:3711-20. 10.1158/1078-0432.CCR-16-3215 - DOI - PMC - PubMed
    1. Hochmair M, Schenker M, Cobo Dols M, et al. Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. J Thorac Oncol 2025;20:203-18. - PubMed